
Health Dictionary
Reliable, easy-to-read patient information on common medical conditions β written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
Riedel's thyroiditis causes
Introduction
Overview
Overview
Riedel’s thyroiditis is considered to have autoimmune etiology and may be caused by the eosinophilia and the proliferation fibroblast as a result of cytokines released by inflammatory cells. Although some drugs such as methysergide, serotonin, lysergic acid, and ergotamine have also been identified as the cause of retroperitoneal fibrosis, there are no reports of the direct association with Riedel’s thyroiditis.
Causes
Causes
Causes of Riedel’s thyroiditis may include:[1]_The_Journal_of_Clinical_Endocrinology_&_Metabolism_|_Oxford_Academic-2|[2][3][4]
Common Causes
- Autoimmunity
- T and B Lymphocyte and macrophage infiltration
- Eosinophilic infiltration
Less common causes
- Drugs
- There are no reports of the direct association with Riedel’s thyroiditis with drugs. Some drugs have been identified as the cause of retroperitoneal fibrosis. As Riedels’ thyroiditis can develop as a manifestation of multi organ fibrosis these drugs are still relevant even though the direct link is not established. Some of the drugs which can cause retroperitoneal fibrosis are:
References
References
- β Guimaraes VC, Ajjan RA, Weetman AP. “Subacute and Reidel’s thyroiditis”.
- _The_Journal_of_Clinical_Endocrinology_&_Metabolism_|_Oxford_Academic_2-0|β “Tissue eosinophilia and eosinophil degranulation in Riedel’s invasive fibrous thyroiditis | The Journal of Clinical Endocrinology & Metabolism | Oxford Academic”.
- β Ormond JK (1965). “Idiopathic retroperitoneal fibrosis: a discussion of the etiology”. J. Urol. 94 (4): 385β90. PMIDΒ 5839568.
- β Iversen BM, Johannesen JW, Nordahl E, Ofstad J, Thunold S, Willassen Y (1975). “Retroperitoneal fibrosis during treatment with methydopa”. Lancet. 2 (7929): 302β4. PMIDΒ 50510.
ββ
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Furqan M M. M.B.B.S[2]
